# reload+after+2024-01-23 03:46:53.759910
address1§60 Leveroni Court
city§Novato
state§CA
zip§94949
country§United States
phone§415 483 8800
website§https://www.ultragenyx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111 (ABO-102), an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
fullTimeEmployees§1311
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Emil D. Kakkis M.D., Ph.D.', 'age': 63, 'title': 'Founder, President, CEO & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1366354, 'exercisedValue': 0, 'unexercisedValue': 1888758}, {'maxAge': 1, 'name': 'Mr. John Richard Pinion II', 'age': 57, 'title': 'Chief Quality Operations Officer & Executive VP of Translational Sciences', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 806193, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Erik  Harris', 'age': 52, 'title': 'Executive VP & Chief Commercial Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 848237, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Howard  Horn', 'age': 45, 'title': 'Executive VP & CFO', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Theodore A. Huizenga', 'age': 52, 'title': 'Senior VP, Corporate Controller & Principal Accounting Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Dennis Karl Huang', 'age': 58, 'title': 'Chief Technical Operations Officer & Gene Therapy Operations and Executive VP', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 331330, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Danielle  Keatley', 'title': 'Senior Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Karah Herdman Parschauer J.D.', 'age': 45, 'title': 'Chief Legal Officer & Executive VP', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 595010, 'exercisedValue': 122000, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ernie W. Meyer', 'age': 59, 'title': 'Chief Human Resources Officer & Executive VP', 'yearBorn': 1964, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas R. Kassberg', 'age': 63, 'title': 'Chief Business Officer & Executive VP', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 714838, 'exercisedValue': 0, 'unexercisedValue': 6082348}]
auditRisk§2
boardRisk§1
compensationRisk§4
shareHolderRightsRisk§7
overallRisk§4
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.694
priceToSalesTrailing12Months§9.528518
currency§USD
dateShortInterest§1702598400
forwardEps§-6.11
pegRatio§-0.65
exchange§NMS
quoteType§EQUITY
shortName§Ultragenyx Pharmaceutical Inc.
longName§Ultragenyx Pharmaceutical Inc.
firstTradeDateEpochUtc§1391178600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b052b015-0bd3-3428-acad-e3223ac2e5e2
gmtOffSetMilliseconds§-18000000
targetHighPrice§140.0
targetLowPrice§43.0
targetMeanPrice§89.7
targetMedianPrice§81.5
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§20
quickRatio§2.054
grossMargins§-0.69958
ebitdaMargins§-1.38965
trailingPegRatio§None
